TORONTO--()--According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for clot management devices is a mixture of relatively mature and dynamic, fast-growing segments. While its average annual growth through 2017 will be 4.1 percent, several more dynamic segments, such as endovascular treatments for deep vein thrombosis (DVT) and acute ischemic stroke (AIS) show much greater growth potential.
“The most significant limiting factor to growth in this market is the lack of clinical data demonstrating the benefits of clot management procedures as compared to systemic thrombolysis”
DVT causes 600,000 hospitalizations, and the resulting pulmonary embolisms cause more than 100,000 deaths annually in the US. Increasing physician awareness of the endovascular treatment options for DVT and for preventing pulmonary embolism will boost procedure volume growth of pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) devices. Growth will be limited somewhat by the need for specific training to maximize effectiveness and safety. Clinical fellowships and training workshops provided by device manufacturers will be key to promoting the next-generation devices recently introduced.
The neurovascular embolectomy device segment, which includes devices used in the interventional treatment of AIS, has significant growth potential. Recent technological innovation has improved the functional benefits of these devices for AIS treatment. In 2012, Covidien launched the Solitaire FR revascularization device and Stryker released the Trevo Pro and Trevo ProVue devices in the US market. These premium-priced devices not only achieve significantly higher rates of revascularization than the first-to-market Merci Retriever device, but also offer significantly improved ease-of-use for physicians.
“The most significant limiting factor to growth in this market is the lack of clinical data demonstrating the benefits of clot management procedures as compared to systemic thrombolysis,” said MRG Analyst Tony Su. “Recent clinical trials did not find better outcomes from including thrombectomy. Device manufacturers have begun funding prospective, randomized clinical trials with the aim of providing the level of clinical evidence that is necessary to justify AIS patient referrals to neurovascular embolectomy.”
Millennium Research Group’s US Markets for Clot Management Devices 2013 report includes unit, installed base, average selling price and revenue information, along with market drivers and limiters and competitive landscape for percutaneous thrombectomy devices, embolectomy balloon catheters, catheter-directed thrombolysis (CDT) devices and inferior vena cava filters (IVCFs) in the United States.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.